---
title: "Methamphetamine reshapes immune cell and plasma signatures in people with HIV"
id: "medrxiv-14-methamphetamine-use-reshapes-cellular-and-plasma-immune-signatures-in-a-lineage"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-14-methamphetamine-use-reshapes-cellular-and-plasma-immune-signatures-in-a-lineage"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.19.26368492v1?rss=1"
published_at: "2026-11-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Methamphetamine reshapes immune cell and plasma signatures in people with HIV
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-14-methamphetamine-use-reshapes-cellular-and-plasma-immune-signatures-in-a-lineage
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.19.26368492v1?rss=1)
- **Published At:** 2026-11-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The investigators performed a cross-sectional, observational study combining single-cell RNA sequencing of peripheral blood mononuclear cells (PBMCs) and targeted plasma proteomics to compare three groups: controls without HIV, people with HIV (PWH) without methamphetamine use, and PWH who use methamphetamine; a larger plasma cohort also included PWH who use cocaine as a stimulant comparator. - Single-cell analyses revealed lineage-specific and often opposite-direction effects of methamphetamine on HIV-associated immune programs; the study team observed reversal of many HIV-associated changes in **monocytes** and **CD8+ T cells**, while other programs persisted in CD4+ and γδ T cells. - In monocytes, pathway scores for interferon responses, antigen presentation, and JAK–STAT signaling shifted with methamphetamine use relative to PWH without stimulant exposure. - CD8+ T cells in Meth+HIV participants showed altered IFN-γ, IL-2 and MYC program activity; central memory CD8+ cells demonstrated reduced type 1 effector programs. - Proliferative signatures and TNF signaling associated with HIV remained in CD4+ and γδ T cell populations of Meth+HIV participants, indicating selective persistence of certain dysregulated programs. - Targeted plasma proteomics found an HIV-associated cytotoxic lymphocyte activation signature (KLRK1, **IFN-γ**, TNF, granzyme B, CXCL9) that was further elevated in PWH who use methamphetamine; methamphetamine use was also associated with higher plasma **IL-6**, **CXCL13** and neurofilament heavy chain. - Network analysis of plasma proteins identified **IFN-γ** as the most connected node, linking a cytotoxic module to a lymphoid chemokine module, according to the authors. - The investigators propose **IFN-γ** signaling—acting through monocyte antigen presentation and CD8+ T cell effector programs—together with TNF, IL-6 and CXCL13, as candidate mediators of neuroimmune dysfunction in PWH who use methamphetamine. - The report noted that all study procedures were IRB-approved and that data are available upon reasonable request; the source did not report experimental dosing, longitudinal follow-up, or sample size details in the abstract and summary text provided.
## Clinical Analysis & Structured Key Points
Methamphetamine use reshapes cellular and plasma immune signatures in a lineage-specific manner in people with HIV | medRxiv Skip to main content Methamphetamine use reshapes cellular and plasma immune signatures in a lineage-specific manner in people with HIV Jonathon P. Sens , Ashish Kumar , Sheri L. Towe , Sun H. Park , Fang-Chi Hsu , Kip D. Zimmerman , Ashish K. Khanna , Kiran K. Solingapuram Sai , E. Alfonso Romero-Sandoval , Gagan Deep , Christina S. Meade , Drew D. Kiraly doi: https://doi.org/10.64898/2026.11.19.26368492 Jonathon P. Sens 1 Wake Forest School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ashish Kumar 1 Wake Forest School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sheri L. Towe 1 Wake Forest School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sun H. Park 1 Wake Forest School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Fang-Chi Hsu 1 Wake Forest School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kip D. Zimmerman 1 Wake Forest School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ashish K. Khanna 1 Wake Forest School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kiran K. Solingapuram Sai 1 Wake Forest School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site E. Alfonso Romero-Sandoval 1 Wake Forest School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Gagan Deep 1 Wake Forest School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christina S. Meade 1 Wake Forest School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Drew D. Kiraly 2 Wake Forest University School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: drew.kiraly{at}advocatehealth.org Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Methamphetamine use is common among people with HIV (PWH) and is associated with worse neurocognitive and clinical outcomes, but how it reshapes HIV-associated immune dysregulation across cell types and compartments is unknown. In this cross-sectional and observational study, we performed single-cell RNA sequencing of peripheral blood mononuclear cells (PBMCs) from controls without HIV, PWH without methamphetamine use and PWH who use methamphetamine, then scored pathway enrichment, cytokine response and transcription factor activity in each cell population. We then profiled plasma from the same three groups in a larger set of participants by targeted proteomics, with PWH who use cocaine added as a stimulant comparison. In the single-cell data, methamphetamine use acted in opposite directions across lineages. HIV-associated changes were reversed most often in monocytes and CD8+ T cells, with interferon, antigen presentation and JAK-STAT programs shifting in monocytes and IFN-γ, IL-2 and MYC programs shifting in CD8+ T cells, whereas HIV-associated proliferative and TNF signaling programs persisted in CD4+ and γδ T cells of Meth+HIV participants. Central memory CD8+ T cells of Meth+HIV participants showed reduced type 1 effector programs. In plasma, HIV was associated with a cytotoxic lymphocyte activation signature (KLRK1, IFN-γ, TNF, granzyme B and CXCL9) that was further elevated with methamphetamine use, together with higher IL-6, CXCL13 and neurofilament heavy chain. IFN-γ was the most connected protein in the plasma interaction network, linking a cytotoxic module to a lymphoid chemokine module. These data define lineage- and compartment-specific immune consequences of methamphetamine use in PWH and nominate IFN-γ signaling, acting through monocyte antigen presentation and CD8+ T cell effector programs, together with TNF, IL-6 and CXCL13, as candidate mediators of neuroimmune dysfunction in PWH who use methamphetamine. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Study procedures were approved by the Advocate Health - Wake Forest University School of Medicine Institutional Review Board, and all participants provided written informed consent prior to completing any study activities. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors. Funder Information Declared National Institute on Drug Abuse , DA061952 , DA052827 , DA066156 , DA063642 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted November 20, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Methamphetamine use reshapes cellular and plasma immune signatures in a lineage-specific manner in people with HIV Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Methamphetamine use reshapes cellular and plasma immune signatures in a lineage-specific manner in people with HIV Jonathon P. Sens , Ashish Kumar , Sheri L. Towe , Sun H. Park , Fang-Chi Hsu , Kip D. Zimmerman , Ashish K. Khanna , Kiran K. Solingapuram Sai , E. Alfonso Romero-Sandoval , Gagan Deep , Christina S. Meade , Drew D. Kiraly medRxiv 2026.11.19.26368492; doi: https://doi.org/10.64898/2026.11.19.26368492 Share This Article: Copy Citation Tools Methamphetamine use reshapes cellular and plasma immune signatures in a lineage-specific manner in people with HIV Jonathon P. Sens , Ashish Kumar , Sheri L. Towe , Sun H. Park , Fang-Chi Hsu , Kip D. Zimmerman , Ashish K. Khanna , Kiran K. Solingapuram Sai , E. Alfonso Romero-Sandoval , Gagan Deep , Christina S. Meade , Drew D. Kiraly medRxiv 2026.11.19.26368492; doi: https://doi.org/10.64898/2026.11.19.26368492 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (642) Allergy and Immunology (928) Anesthesia (355) Cardiovascular Medicine (5060) Dentistry and Oral Medicine (496) Dermatology (433) Emergency Medicine (681) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1704) Epidemiology (16353) Forensic Medicine (37) Gastroenterology (1250) Genetic and Genomic Medicine (7334) Geriatric Medicine (761) Health Economics (1101) Health Informatics (5352) Health Policy (1480) Health Systems and Quality Improvement (1847) Hematology (604) HIV/AIDS (1389) Infectious Diseases (except HIV/AIDS) (16537) Intensive Care and Critical Care Medicine (1210) Medical Education (702) Medical Ethics (157) Nephrology (757) Neurology (7669) Nursing (380) Nutrition (1144) Obstetrics and Gynecology (1308) Occupational and Environmental Health (1046) Oncology (3769) Ophthalmology (1105) Orthopedics (414) Otolaryngology (474) Pain Medicine (508) Palliative Medicine (144) Pathology (727) Pediatrics (1877) Pharmacology and Therapeutics (759) Primary Care Research (793) Psychiatry and Clinical Psychology (6187) Public and Global Health (10051) Radiology and Imaging (2562) Rehabilitation Medicine and Physical Therapy (1540) Respiratory Medicine (1280) Rheumatology (666) Sexual and Reproductive Health (814) Sports Medicine (601) Surgery (809) Toxicology (109) Transplantation (321) Urology (309)
## Related Clinical Research

- [Impact of loss to follow-up on 5-year mortality after tuberculosis treatment in São Paulo, Brazil](https://medichelpline.com/clinical-feed/plos-medicine-0-loss-to-follow-up-during-tuberculosis-treatment-and-5-year-mortality-in-brazil.md)
- [Barriers and facilitators of oral PrEP uptake and persistence among MSM in Cape Town](https://medichelpline.com/clinical-feed/medrxiv-12-understanding-oral-prep-uptake-and-persistence-among-gay-men-and-other-men-who.md)
- [Earlier 3‑Month Viral Load Testing and Longer Visit Intervals After South Africa’s 2023 ART Guidel](https://medichelpline.com/clinical-feed/medrxiv-23-uptake-and-outcomes-of-earlier-viral-load-testing-and-longer-visit-intervals-in.md)
- [Nuclear-transport–targeting peptides (SN50 family) as broad anti-inflammatory agents](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-targeting-the-nuclear-gateway-a-new-class-of-cell-penetrating-peptides-for.md)
- [HIV Infection Linked to Higher 2‑Year MACE Risk in Chinese Patients with Carotid Atherosclerosis](https://medichelpline.com/clinical-feed/pubmed-42980188.md) (DOI: 10.1080/07853890.2026.2753324)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.